Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: Involvement of oxidative stress and cholinergic dysfunction

Free Radical Biology and Medicine

Volumn 52, Issue 8, 2012, Pages 1443-1452

  Zhang, Wei ^a   Bai, Miao ^a   Xi, Ye ^a   Hao, Jian ^a   Liu, Liu ^a   Mao, Ni ^a   Su, Changjun ^a   Miao, Jianting ^a   Li, Zhuyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer disease; Amyloid protein; Cholinergic function; Cognitive deficit; Free radicals; Oxidative stress; Transgenic mice

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; CARBONYL DERIVATIVE; CHOLINE ACETYLTRANSFERASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPATIAL MEMORY;

ACETYLCHOLINE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHOLINE O-ACETYLTRANSFERASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE PEROXIDASE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; RECEPTORS, CHOLINERGIC; SUPEROXIDE DISMUTASE;

MUS; MUS MUSCULUS;

EID: 84862782041     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.01.023     Document Type: Article

References (96)

1. Kawas, C. H.; Corrada, M. M. Alzheimer's and dementia in the oldest-old: a century of challenges. Curr. Alzheimer Res. 3:411-419; 2006.
2. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:383-388; 1991.
3. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185; 1992.
4. Blennow, K.; Bogdanovic, N.; Alafuzoff, I.; Ekman, R.; Davidsson, P. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J. Neural Transm. 103: 603-618; 1996.
5. Berg, L.; McKeel Jr., D. W.; Miller, J. P.; Storandt, M.; Rubin, E. H.; Morris, J. C.; Baty, J.; Coats, M.; Norton, J.; Goate, A. M.; Price, J. L.; Gearing, M.; Mirra, S. S.; Saunders, A. M. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55:326-335; 1998.
6. Giannakopoulos, P.; Herrmann, F. R.; Bussière, T.; Bouras, C.; Kövari, E.; Perl, D. P.; Morrison, J. H.; Gold, G.; Hof, P. R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60:1495-1500; 2003.
7. Giannakopoulos, P.; Kövari, E.; Gold, G.; von Gunten, A.; Hof, P. R.; Bouras, C. Pathological substrates of cognitive decline in Alzheimer's disease. Front. Neurol. Neurosci. 24:20-29; 2009.
8. Dodart, J. C.; Meziane, H.; Mathis, C.; Bales, K. R.; Paul, S. M.; Ungerer, A. Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein. Behav. Neurosci. 113:982-990; 1999.
9. Puoliväli, J.; Wang, J.; Heikkinen, T.; Heikkilä, M.; Tapiola, T.; van Groen, T.; Tanila, H. Hippocampal Aβ 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol. Dis. 9:339-347; 2002.
10. Zhang, W.; Hao, J.; Liu, R.; Zhang, Z.; Lei, G.; Su, C.; Miao, J.; Li, Z. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 222:342-350; 2011.
11. McLean, C. A.; Cherny, R. A.; Fraser, F. W.; Fuller, S. J.; Smith, M. J.; Beyreuther, K.; Bush, A. I.; Masters, C. L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:860-866; 1999.
12. Tabaton, M.; Piccini, A. Role of water-soluble amyloid-β in the pathogenesis of Alzheimer's disease. Int. J. Exp. Pathol. 86:139-145; 2005.
13. Watson, D.; Castaño, E.; Kokjohn, T. A.; Kuo, Y. M.; Lyubchenko, Y.; Pinsky, D.; Connolly Jr., E. S.; Esh, C.; Luehrs, D. C.; Stine, W. B.; Rowse, L. M.; Emmerling, M. R.; Roher, A. E. Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer's disease. Neurol. Res. 27:869-881; 2005.
14. Steinerman, J. R.; Irizarry, M.; Scarmeas, N.; Raju, S.; Brandt, J.; Albert, M.; Blacker, D.; Hyman, B.; Stern, Y. Distinct pools of β-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch. Neurol. 65:906-912; 2008.
15. Zerbinatti, C. V.; Wozniak, D. F.; Cirrito, J.; Cam, J. A.; Osaka, H.; Bales, K. R.; Zhuo, M.; Paul, S. M.; Holtzman, D. M.; Bu, G. Increased soluble amyloid-β peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. U. S. A. 101:1075-1080; 2004.
16. Lindner, M. D.; Hogan, J. B.; Krause, R. G.; Machet, F.; Bourin, C.; Hodges Jr., D. B.; Corsa, J. A.; Barten, D. M.; Toyn, J. H.; Stock, D. A.; Rose, G. M.; Gribkoff, V. K. Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice. Behav. Brain Res. 173:62-75; 2006.
17. Lefterov, I.; Fitz, N. F.; Cronican, A.; Lefterov, P.; Staufenbiel, M.; Koldamova, R. Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers. ASN Neurol. 1:e00006; 2009.
18. Holcomb, L.; Gordon, M. N.; McGowan, E.; Yu, X.; Benkovic, S.; Jantzen, P.; Wright, K.; Saad, I.; Mueller, R.; Morgan, D.; Sanders, S.; Zehr, C.; O'Campo, K.; Hardy, J.; Prada, C. M.; Eckman, C.; Younkin, S.; Hsiao, K.; Duff, K. Accelerated Alzheimertype phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:97-100; 1998.
19. Holcomb, L. A.; Gordon, M. N.; Jantzen, P.; Hsiao, K.; Duff, K.; Morgan, D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29:177-185; 1999.
20. Koistinaho, M.; Ort, M.; Cimadevilla, J. M.; Vondrous, R.; Cordell, B.; Koistinaho, J.; Bures, J.; Higgins, L. S. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. U. S. A. 98:14675-14680; 2001.
21. Richardson, J. C.; Kendal, C. E.; Anderson, R.; Priest, F.; Gower, E.; Soden, P.; Gray, R.; Topps, S.; Howlett, D. R.; Lavender, D.; Clarke, N. J.; Barnes, J. C.; Haworth, R.; Stewart, M. G.; Rupniak, H. T. Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 122:213-228; 2003.
22. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102; 1996.
23. Arendash, G. W.; King, D. L.; Gordon, M. N.; Morgan, D.; Hatcher, J. M.; Hope, C. E.; Diamond, D. M. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:42-53; 2001.
24. Chapman, P. F.; White, G. L.; Jones, M. W.; Cooper-Blacketer, D.; Marshall, V. J.; Irizarry, M.; Younkin, L.; Good, M. A.; Bliss, T. V.; Hyman, B. T.; Younkin, S. G.; Hsiao, K. K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:271-276; 1999.
25. King, D. L.; Arendash, G. W.; Crawford, F.; Sterk, T.; Menendez, J.; Mullan, M. J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 103:145-162; 1999.
26. Knobloch, M.; Konietzko, U.; Krebs, D. C.; Nitsch, R. M. Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice. Neurobiol. Aging 28:1297-1306; 2007.
27. Praticò, D.; Uryu, K.; Leight, S.; Trojanoswki, J. Q.; Lee, V. M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21:4183-4187; 2001.
28. Schuessel, K.; Schäfer, S.; Bayer, T. A.; Czech, C.; Pradier, L.; Müller-Spahn, F.; Müller, W. E.; Eckert, A. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis. 18:89-99; 2005.
29. Jazi, R.; Lalonde, R.; Qian, S.; Strazielle, C. Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice. Neurosci. Res. 63:106-114; 2009.
30. Watanabe, T.; Yamagata, N.; Takasaki, K.; Sano, K.; Hayakawa, K.; Katsurabayashi, S.; Egashira, N.; Mishima, K.; Iwasaki, K.; Fujiwara, M. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. 1249:222-228; 2009.
31. Garcia-Alloza, M.; Robbins, E. M.; Zhang-Nunes, S. X.; Purcell, S. M.; Betensky, R. A.; Raju, S.; Prada, C.; Greenberg, S. M.; Bacskai, B. J.; Frosch, M. P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24:516-524; 2006.
32. Ruan, L.; Kang, Z.; Pei, G.; Le, Y. Amyloid deposition and inflammation in APPswe/ PS1dE9 mouse model of Alzheimer's disease. Curr. Alzheimer Res. 6: 531-540; 2009.
33. Shemer, I.; Holmgren, C.; Min, R.; Fülöp, L.; Zilberter, M.; Sousa, K. M.; Farkas, T.; Härtig, W.; Penke, B.; Burnashev, N.; Tanila, H.; Zilberter, Y.; Harkany, T. Non-fibrillar β-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur. J. Neurosci. 23:2035-2047; 2006.
34. Hu, Y. S.; Xu, P.; Pigino, G.; Brady, S. T.; Larson, J.; Lazarov, O. Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/ PS1DeltaE9 mice. FASEB J. 24:1667-1681; 2010.
35. Pistell, P. J.; Zhu, M.; Ingram, D. K. Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience 152:594-600; 2008.
36. Bonardi, C.; de Pulford, F.; Jennings, D.; Pardon, M. C. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease. Behav. Brain Res. 222:89-97; 2011.
37. Jankowsky, J. L.; Fadale, D. J.; Anderson, J.; Xu, G. M.; Gonzales, V.; Jenkins, N. A.; Copeland, N. G.; Lee, M. K.; Younkin, L. H.; Wagner, S. L.; Younkin, S. G.; Borchelt, D. R. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum. Mol. Genet. 13:159-170; 2004.
38. Savonenko, A.; Xu, G. M.; Melnikova, T.; Morton, J. L.; Gonzales, V.; Wong, M. P.; Price, D. L.; Tang, F.; Markowska, A. L.; Borchelt, D. R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18: 602-617; 2005.
39. O'Leary, T. P.; Brown, R. E. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 201:120-127; 2009.
40. Miao, J.; Vitek, M. P.; Xu, F.; Previti, M. L.; Davis, J.; Van Nostrand, W. E. Reducing cerebral microvascular amyloid-β protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J. Neurosci. 25:6271-6277; 2005.
41. Ruan, C. J.; Li, Z.; Zhang, L.; Chen, D. H.; Du, G. H.; Sun, L. Protective effects of trans-2,4-dimethoxystilbene on cognitive impairments induced by Aβ(25-35) in hypercholesterolemic rats. Brain Res. Bull. 82:251-258; 2010.
42. Lin, Z. H.; Xiao, Z. B.; Zhu, D. N.; Yan, Y. Q.; Yu, B. Y.; Wang, Q. J. Aqueous extracts of FBD, a Chinese herb formula composed of Poria cocos, Atractylodes macrocephala, and Angelica sinensis reverse scopolamine induced memory deficit in ICR mice. Pharm. Biol. 47:396-401; 2009.
43. Xing, B.; Chen, H.; Zhang, M.; Zhao, D.; Jiang, R.; Liu, X.; Zhang, S. Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat. Stroke 39:2362-2369; 2008.
44. Wei, X.; Liu, H.; Sun, X.; Fu, F.; Zhang, X.; Wang, J.; An, J.; Ding, H. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci. Lett. 386:58-62; 2005.
45. Lue, L. F.; Kuo, Y. M.; Roher, A. E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; Kurth, J. H.; Rydel, R. E.; Rogers, J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:853-862; 1999.
46. Wang, J.; Dickson, D. W.; Trojanowski, J. Q.; Lee, V. M. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158:328-337; 1999.
47. Hérard, A. S.; Delzescaux, T.; Cornet, S.; Lebenberg, J.; Chabrier, P. E.; Hantraye, P.; Dhenain, M. Memory loss in young APPswe/PS1dE9 mice and associated changes in brain metabolism analyzed using a 3-D voxel-based approach. Alzheimers Dement. 5:8-9; 2009.
48. Van Dam, D.; D'Hooge, R.; Staufenbiel, M.; Van Ginneken, C.; Van Meir, F.; De Deyn, P. P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17:388-396; 2003.
49. Westerman, M. A.; Cooper-Blacketer, D.; Mariash, A.; Kotilinek, L.; Kawarabayashi, T.; Younkin, L. H.; Carlson, G. A.; Younkin, S. G.; Ashe, K. H. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:1858-1867; 2002.
50. Vorhees, C. V.; Williams, M. T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1:848-858; 2006.
51. Koistinaho, M.; Ort, M.; Cimadevilla, J. M.; Vondrous, R.; Cordell, B.; Koistinaho, J.; Bures, J.; Higgins, L. S. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. U. S. A. 98:14675-14680; 2001.
52. Marchetti, C.; Marie, H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? Rev. Neurosci. 22: 373-402; 2011.
53. Gengler, S.; Hamilton, A.; Hölscher, C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One 5:e9764; 2010.
54. Giacchino, J.; Criado, J. R.; Games, D.; Henriksen, S. In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice. Brain Res. 876: 185-190; 2000.
55. Balducci, C.; Tonini, R.; Zianni, E.; Nazzaro, C.; Fiordaliso, F.; Salio, M.; Vismara, L.; Gardoni, F.; Di Luca, M.; Carli, M.; Forloni, G. Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AßPP23 transgenic mice. J. Alzheimers Dis. 21:1367-1381; 2010.
56. Klein, W. L.; Krafft, G. A.; Finch, C. E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24:219-224; 2001.
57. Perry, E.; Walker, M.; Grace, J.; Perry, R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22:273-280; 1999.
58. Bierer, L. M.; Haroutunian, V.; Gabriel, S.; Knott, P. J.; Carlin, L. S.; Purohit, D. P.; Perl, D. P.; Schmeidler, J.; Kanof, P.; Davis, K. L. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64:749-760; 1995.
59. Shinotoh, H.; Namba, H.; Fukushi, K.; Nagatsuka, S.; Tanaka, N.; Aotsuka, A.; Ota, T.; Tanada, S.; Irie, T. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann. Neurol. 48:194-200; 2000.
60. Auld, D. S.; Kornecook, T. J.; Bastianetto, S.; Quirion, R. Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68:209-245; 2002.
61. Bartus, R. T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten: a generation following the cholinergic hypothesis. Exp. Neurol. 163:495-529; 2000.
62. Bartus, R. T.; Dean III, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414; 1982.
63. Schliebs, R. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with β-amyloid, inflammation and neurotrophin signaling. Neurochem. Res. 30:895-908; 2005.
64. Hernandez, D.; Sugaya, K.; Qu, T.; McGowan, E.; Duff, K.; McKinney, M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 12: 1377-1384; 2001.
65. German, D. C.; Yazdani, U.; Speciale, S. G.; Pasbakhsh, P.; Games, D.; Liang, C. L. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. 462:371-381; 2003.
66. Kar, S.; Issa, A. M.; Seto, D.; Auld, D. S.; Collier, B.; Quirion, R. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J. Neurochem. 70:2179-2187; 1998.
67. 3H] acetylcholine release in retinal neurons: involvement of metabolic dysfunction. Amyloid 9:221-228; 2002.
68. Nakamura, S.; Murayama, N.; Noshita, T.; Annoura, H.; Ohno, T. Progressive brain dysfunction following intracerebroventricular infusion of β(1-42)-amyloid peptide. Brain Res. 912:128-136; 2001.
69. Bales, K. R.; Tzavara, E. T.; Wu, S.; Wade, M. R.; Bymaster, F. P.; Paul, S. M.; Nomikos, G. G. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody. J. Clin. Invest. 116:825-832; 2006.
70. Watanabe, T.; Iwasaki, K.; Ishikane, S.; Naitou, T.; Yoshimitsu, Y.; Yamagata, N.; Ozdemir, M. B.; Takasaki, K.; Egashira, N.; Mishima, K.; Fujiwara, M. Spatial memory impairment without apoptosis induced by the combination of β-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats. J. Pharmacol. Sci. 106:84-91; 2008.
71. Sonnen, J. A.; Breitner, J. C.; Lovell, M. A.; Markesbery, W. R.; Quinn, J. F.; Montine, T. J. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic. Biol. Med. 45:219-230; 2008.
72. Keller, J. N.; Schmitt, F. A.; Scheff, S. W.; Ding, Q.; Chen, Q.; Butterfield, D. A.; Markesbery, W. R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152-1156; 2005.
73. Butterfield, D. A.; Reed, T.; Newman, S. F.; Sultana, R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43: 658-677; 2007.
74. Praticò, D.; Uryu, K.; Leight, S.; Trojanoswki, J. Q.; Lee, V. M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21:4183-4187; 2001.
75. Abdul, H. M.; Sultana, R.; St Clair, D. K.; Markesbery, W. R.; Butterfield, D. A. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 45:1420-1425; 2008.
76. Resende, R.; Moreira, P. I.; Proença, T.; Deshpande, A.; Busciglio, J.; Pereira, C.; Oliveira, C. R. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic. Biol. Med. 44:2051-2057; 2008.
77. Butterfield, D. A.; Galvan, V.; Lange, M. B.; Tang, H.; Sowell, R. A.; Spilman, P.; Fombonne, J.; Gorostiza, O.; Zhang, J.; Sultana, R.; Bredesen, D. E. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic. Biol. Med. 48:136-144; 2010.
78. Butterfield, D. A.; Drake, J.; Pocernich, C.; Castegna, A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med. 7:548-554; 2001.
79. Butterfield, D. A.; Lauderback, C. M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32: 1050-1060; 2002.
80. Chauhan, V.; Chauhan, A. Oxidative stress in Alzheimer's disease. Pathophysiology 13:195-208; 2006.
81. Cardoso, S. M.; Oliveira, C. R. Glutathione cycle impairment mediates Aβ-induced cell toxicity. Free Radic. Res. 37:241-250; 2003.
82. Melo, J. B.; Agostinho, P.; Oliveira, C. R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid β-peptide. Neurosci. Res. 45:117-127; 2003.
83. Jhoo, J. H.; Kim, H. C.; Nabeshima, T.; Yamada, K.; Shin, E. J.; Jhoo, W. K.; Kim, W.; Kang, K. S.; Jo, S. A.; Woo, J. I. β-Amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav. Brain Res. 155:185-196; 2004.
84. Butterfield, D. A.; Lauderback, C. M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32: 1050-1060; 2002.
85. Butterfield, D. A.; Reed, T.; Newman, S. F.; Sultana, R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43: 658-677; 2007.
86. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E. K.; Jones, P. K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C. S.; Petersen, R. B.; Smith, M. A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:759-767; 2001.
87. Beal, M. F. Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 26:585-586; 2005.
88. Lovell, M. A.; Markesbery, W. R. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J. Neurosci. Res. 85:3036-3040; 2007.
89. Halliwell, B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716; 2001.
90. Ikonomidou, C.; Kaindl, A. M. Neuronal death and oxidative stress in the developing brain. Antioxid. Redox Signal. 14:1535-1550; 2011.
91. Floyd, R. A.; Carney, J. M. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann. Neurol. 32:S22-S27; 1992.
92. Avrova, N. F.; Victorov, I. V.; Tyurin, V. A.; Zakharova, I. O.; Sokolova, T. V.; Andreeva, N. A.; Stelmaschuk, E. V.; Tyurina, Y. Y.; Gonchar, V. S. Inhibition of glutamate-induced intensification of free radical reactions by gangliosides: possible role in their protective effect in rat cerebellar granule cells and brain synaptosomes. Neurochem. Res. 23:945-952; 1998.
93. Castegna, A.; Thongboonkerd, V.; Klein, J. B.; Lynn, B.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85:1394-1401; 2003.
94. Reed, T. T.; Pierce Jr., W. M.; Turner, D. M.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J. Cell. Mol. Med. 13:2019-2029; 2009.
95. Reed, T.; Perluigi, M.; Sultana, R.; Pierce, W. M.; Klein, J. B.; Turner, D. M.; Coccia, R.; Markesbery, W. R.; Butterfield, D. A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30:107-120; 2008.
96. Boyd-Kimball, D.; Castegna, A.; Sultana, R.; Poon, H. F.; Petroze, R.; Lynn, B. C.; Klein, J. B.; Butterfield, D. A. Proteomic identification of proteins oxidized by Aβ(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res. 1044:206-215; 2005.